Please assess the completion status of the following clinical trial:

Trial Title: Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~Generally healthy; LDL-C level in serum or plasma ≥ 100 mg/dL and \< 190 mg/dL at Screening.~Exclusion criteria:~* LDL-C ≥ 160 mg/dL at Screening if more than 2 major Coronary Heart Disease risk factors, as defined in National Cholesterol Education Program guidelines.~* Receiving treatment of any kind for hyperlipidemia within 6 weeks of enrollment.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo - Alirocumab (Type: EXPERIMENTAL): Injection through subcutaneous (SC) administration, placebo for 4 weeks then, alirocumab for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).